Open AccessPembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?
Author(s) -
Matthew R. Zibelman,
Elizabeth R. Plimack
Publication year - 2019
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2019.04.57
Subject(s) - pembrolizumab , ipilimumab , renal cell carcinoma , medicine , nivolumab , melanoma , oncology , immunotherapy , cancer research , pharmacology , cancer